This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Sci-B-Vac™ is a recombinant, hepatitis B vaccine derived from a mammalian cell line and containing hepatitis B surface antigen (HBsAg) as well as preS1 and preS2 antigens. Few studies have been performed on the antibody responses to preS1 in relation to the antibody to hepatitis B surface antigen (anti-HBs) response during immunisation of healthy children with preS-containing vaccines.
Results
In this study 28 healthy newborns were randomly selected to receive either 2.5 ug or 5.0 ug of the Sci-B-Vac vaccine. Children received three doses of vaccine according to a 0-, 1-, 6-month scheme. Antibodies against the S-protein and three synthetic peptides mimicking three B-cell preS1 epitopes, (21–32 amino acid epitope), (32–47 amino acid epitope) and the C-terminal (amino acid epitope 94–117) were determined at 6 and 9 months. Fourteen (50%) of the 28 newborns had detectable levels of anti-preS1 (21–32) antibodies; 15 (54%) were anti-preS1 (32–47) reactive and 12 (43%) were anti-preS1 (94–117) reactive at 6 or 9 months after initiation of the vaccination. Significantly higher levels of anti-HBs were observed in the sera of patients with detectable anti-preS1 (32–47) reactivity (24 550 ± 7375 IU/L, mean ± SEM) as compared with the non-reactive sera (5991 ± 1530 IU/L, p < 0.05). The anti-HBs levels were significantly lower if none (p < 0.05) or one (p < 0.025) of the preS1 (21–32, 32–47, 94–117) peptides were recognised compared with the anti-HBs levels if two or three peptides were recognised.
Conclusion
Recognition of several preS1 epitopes, and in particular, the epitope contained within the second half of the hepatocyte binding site localised in the hepatitis B surface protein of the third-generation hepatitis B vaccine is accompanied by a more pronounced antibody response to the S-gene-derived protein in healthy newborns.
Background
Infectious particles of hepatitis B virus (HBV), called Dane particles, consist of viral nucleic acid encapsulated within a core particle enveloped by three distinct virus-coded surface proteins. These three proteins, termed preS1, preS2 and S, are co-terminal at the C-terminus but are different at the N-terminus end regarding the position of the initiation codon of protein translation of the viral genome [1]. It has been demonstrated that the C-terminal part of the preS1 region is essential for viral assembly [2] whereas the N-terminal part is believed to play a major role in mediating virus attachment and entry into hepatocytes [3]. Within the preS1 protein, the 21–47 amino acid epitope was shown to mediate binding to the cell surface of HepG2 cells [4]. Antibodies directed against this epitope were shown to have virus-neutralising activity [5]. A polypeptide covering the N-terminal region 21–47 could inhibit virus-cell interactions, as does the antibody against this fragment [6-8]. Moreover, the hepatitis B surface antigen(HBsAg) preS1 region is highly immunogenic, containing both sequential and conformational epitopes [9] with abundant T- and B-cell epitopes [10-15].
Thus, multiple viral functions of the preS1 region provide a useful target for anti-HBV intervention. Recombinant preS products have been developed as protein vaccines that elicit B- and T-cell immune responses on a broader range of major histocompatibility complex (MHC) haplotypes [16-19]. Comparative immunogenicity studies in mice, rabbits and humans using one such vaccine (BioHep B/Sci-B-Vac™, also known as Hepimmune) have repeatedly confirmed the excellent immunogenicity measured as antibody to hepatitis B surface antigen (anti-HBs) production and safety of this third-generation HBV vaccine [20]. However, only a few studies have been performed on the antibody responses to preS1 in relation to the anti-HBs response during immunisation of healthy children with preS-containing vaccines.
Recently, we demonstrated that recognition of the preS epitopes contained in the third-generation preS1/preS2/S vaccine (Sci-B-Vac™, BioHepB) is accompanied by a more rapid onset and pronounced antibody response to the S-gene-derived protein in healthy children and newborns [21,22]. To further analyse the specificity and significance of the antibody responses toward the two linear preS1 sequences that have been shown to represent human B cell epitopes within the hepatocyte binding site comprising amino acids preS1 (21–47) [[4,6,7], reviewed in [23]], as well as the C-terminal part comprising amino acids (94–117) [24,25], we measured the specific antibody response in healthy newborns after immunisation with the Sci-B-Vac™ vaccine. Furthermore, we evaluated whether induction of antibodies toward the three preS1 epitopes (21–32, 32–47 and 94–117) is associated with an enhanced response to HBsAg. We found that recognition of several preS1 epitopes, and in particular, the epitope contained within the second half of the hepatocyte binding site localised in the hepatitis B surface protein of the third-generation hepatitis B vaccine is accompanied by a more pronounced antibody response to the S-gene-derived protein in healthy newborns.
MethodsVaccine
Immunisation of newborns was performed with the recombinant Chinese hamster ovary (rCHO) cell-derived Sci-B-Vac™ vaccine, (SciGen Ltd, Singapore, earlier referred to as Bio-Hep-B™ vaccine, Bio-Technology General Corporation) [19]. The vaccine was purified from the culture media of CHO cells transfected with the nucleotide sequences coding for all three surface antigens (i.e. preS1, preS2 and S). The Sci-B-Vac™ vaccine of the HBsAg subtype adw2 and genotype A is > 99% pure and the proteins of the vaccine are absorbed on alum phosphate (0.5 mg/ml); the preservative agent is Thiomerosal (50 ug/ml). The vaccine was stored and transported at 2–8°C. The same batch of vaccine was used throughout the study. The vaccinees received three doses of vaccine according to a 0-, 1-, and 6-month schedule [21].
Study design
Twenty-eight healthy newborns were qualified for vaccination. Fifteen received 2.5 ug doses and 13 received 5.0 ug doses of vaccine. The selection of infants was random. The mothers were negative for hepatitis B markers (HBsAg, antibody to hepatitis B core antigen (anti-HBc) and anti-HBs). The cord blood samples were also negative for these markers. The transaminase levels (ALT) in mother and cord blood samples were within the normal range. The newborns were evaluated within the first 5 min of life as having at least 7 points on the Apgar scale. The newborns' body weight was > 2500 g. Newborns from drug-addicted or alcoholic parents were excluded from the study. Anti-HBs and anti-preS1 antibodies were evaluated at 6 (T6, i.e. 5 months after the second injection) and 9 months (T9, i.e. 3 months after the third injection) after vaccination with the Sci-B-Vac™ vaccine.
In accordance with the Helsinki declaration, parents of all children had signed an informed consent form for participation in the study, The parents were instructed on how the vaccine was tested for safety and immunogenicity in adults and how to observe local signs and general symptoms associated with the vaccine administration. The frequencies of all signs and symptoms (i.e. vaccine reactions) that the parents observed were reported in their diary cards. These signs might include appetite loss, diarrhoea, fever, irritability, sleeplessness and vomiting, as well as the local signs of pain and redness or swelling at the injection site. The study was approved by the Ethics Committee of the Child health Memorial Institute [21].
Antibody detection
Anti-HBs antibodies were measured using a microparticle enzyme immunoassay in an IMX apparatus (Abbott, Chicago, ILL., USA) and expressed as IU/L. Control tests (hepatitis B, anti-HBs from Labquality, Helsinki, Finland) were used throughout the study. Antibodies to preS1 were assessed by enzyme-linked immunosorbent assay (ELISA). Microtitreplates (Immunolon 2, no.011-010-3455, Dynatech, Chantilly, VA, USA) were coated with preS1 (21–32), (32–47), (94–117) (adw2) peptídes (purchased from Sigma Genosys, Cambridge, UK) at a concentration of 2 ug/ml in 0.05 M sodium carbonate buffer (pH 9.6) at 4°C overnight.
Patient and pooled control sera, diluted 1/125 in 0.05 M phosphate-buffered saline (PBS)-Tween-1% foetal bovine serum (FBS), were incubated on the plates at 4°C overnight. The plates were washed and incubated with alkaline phosphatase (ALP)-conjugated goat anti-human gamma chains (A-3187, Sigma Chemical Company, St. Louis, MO, USA) and diluted 1:1000 in PBS-Tween-1% FBS at 4°C overnight. After incubation (5–30 min) with p-nitrophenyl phosphate in diethanolamine HCl, the optical density (OD) at 405 nm was measured in a Titertek Multiskan Plus Photometer (Flow Laboratories, Edinburgh, Scotland). Sera from 20 hepatitis B-susceptible healthy blood donors, routinely tested and lacking serum markers for hepatitis A-E, were pooled and used as controls to obtain the normal (N) value. Positive antibody reactivity was defined as a sample (S) over the N value (S/N ≥ 2.5) equal to the mean OD value plus 4 SD of the control sample.
Specificity tests
Equal volumes of diluted serum samples from anti-preS1 (21–32) or (32–47) reactive individuals and inhibitors (0.125–8.0 ug/mL) were incubated for 4 h at 4°C before addition to the ELISA plates and further analysed as described above. The synthetic peptide analogues preS1 adw2 (21–32), (32–47) or (94–117) were used as inhibitors. The relevant preS1 peptide inhibited the preS1 reactivity to 100% whereas irrelevant preS1 peptides did not (Figures 1 and 2). Anti-preS1 (94–117) specificity has been documented earlier [25].
Inhibition of IgG anti-preS1(21–32) reactivity. A diluted serum sample from an anti-preS1 (21–32) reactive patient was preincubated with different concentrations (0.125–8.0 ug/mL) of the synthetic peptide analogue corresponding to the (black circle) 21–32, (black square) 32–47 or (black rhomboid) 94–117 amino acid sequences of preS1 before assaying in the preS1 (21–32) ELISA.
Inhibition of IgG anti-preS1 (32–47) reactivity. A diluted serum sample from an anti-preS1 (32–47) reactive patient was preincubated with different concentrations (0.125–8.0 ug/mL) of the synthetic peptide analogue corresponding to the (black circle) 21–32, (black square) 32–47 or (black rhomboid) 94–117 amino acid sequences of preS1 before assaying in the preS1 (32–47) ELISA.
Statistical analysis
The non-parametric Mann-Whitney U test was employed to compare data between groups of newborns vaccinated with different doses of the Sci-B-Vac™ vaccine.
Results
The presence of IgG antibodies with specificity for the synthetic peptide analogues corresponding to the preS1 (21–32), (32–47) and (94–117) regions of the HBV was studied using peptide-based ELISA at a 1/125 dilution of sera from 28 newborns after complete immunisation with the Sci-B-Vac™ vaccine. Fourteen (50%) of the 28 newborns had detectable levels of anti-preS1 (21–32) antibodies at 6 or 9 months after initiation of the vaccination. Fifteen (54%) and 12 (43%) newborns were anti-preS1 (32–47) and (94–117) reactive, respectively. No significant difference in response to the preS1 epitopes was noted in newborns immunised with the 2.5 ug or the 5.0 ug vaccine doses.
The mean levels of anti-HBs were significantly higher in the anti-preS1 (32–47) reactive sera (24 550 ± 7375 IU/L, mean ± SEM) as compared with the non-reactive sera (5991 ± 1530 IU/L, p < 0.05) (Table 1). In contrast, no significant difference was noted between anti-preS1 (21–32) or (94–117) reactive group compared with their respective non-reactive groups.
Anti-HBs titres in preS1 (21–32, 32–47 and 94–117) reactive sera compared with non-reactive sera from newborns vaccinated with Bio-HepB™ vaccine
Reactive
Non-reactive
Probability
Anti-preS1 (21–32)
n = 14
n = 14
Anti-HBs IU/L
15 841 ± 4 023
16 026 ± 7 859
ns
Anti-preS1 (32–47)
n = 15
n = 13
Anti-HBs IU/L
24 550 ± 7 375
5 991 ± 1 530
p < 0.05
Anti-preS1 (94–117)
n = 12
n = 16
Anti-HBs IU/L
19 464 ± 5 280
13 286 ± 6 533
ns
ns = not significant
Anti-HBs (mean ± SEM)
Table 2 demonstrates that the anti-HBs levels were significantly lower if none (p < 0.05) or one (p < 0.025) of the preS1 (21–32, 32–47, 94–117) peptides were recognised in comparison with the anti-HBs levels if two or three peptides were recognised.
Anti-HBs levels in vaccinated newborns with different anti-preS1 peptide (21–32, 32–47, 94–117) reactivities at time T9
Reactivity with
Number
Anti-HBs (IU/L)
Probability*
3 preS1 peptides
n = 7
23 688 ± 6 183 a/
2 preS1 peptides
n = 4
22 890 ± 10 670 b/
ns
1 preS1 peptide
n = 12
11 919 ± 8 669 c/
p < 0.025
0 preS1 peptide
n = 5
2 065 ± 1 105 d/
p < 0.05
*the a/ compared with the b/, c/ or d/ groups of vaccinated newborns (Mann-Whitney test)
ns = not significant
T9 = three months after the third injection
Anti-HBs (mean ± SEM)
Discussion
A large number of studies have suggested a direct involvement of the preS1 domain of the hepatitis B virus large envelope protein (L-HBsAg) (in particular amino acids 21 to 47) in a virus attachment to hepatocytes [[4,6,7], reviewed in [23]]. Recently, it was demonstrated that a mutant L-HBsAg bearing a deletion in the 26–30 amino acid sequence of the preS1 receptor binding site was non-infectious and hence deficient in viral entry [3], further supporting the importance of this domain as an infectivity determinant in hepatitis B. The aim in this study was to identify preS1 antibodies reacting with two human antibody binding sites, p (21–32), containing an infectivity determinant and p (32–47), including a previously defined HBV-neutralisation epitope comprising amino acids 37–45 of preS1 that have been identified within this sequence [26] as well as preS1 antibodies reacting with the C-terminal part (94–117) in sera from newborns completely immunised with the third-generation recombinant vaccine (Sci-B-Vac™).
We found that immunised newborns exhibited anti-preS1 (21–32) and anti-preS1 (32–47) and anti-preS1 (94–117) antibody reactivity in 50% (14/28), 54% (15/28) and 43% (12/28), respectively. The prevalence of vaccine-induced anti-peptide antibodies in this study is identical to the prevalence of antibodies reacting with p (21–32), p (32–47) and p (94–117) in sera obtained during convalescence from natural HBV infection [24]. The third-generation vaccine used in this study, Sci-B-Vac™, was developed using mammalian cells, which provide envelope proteins similar to those isolated from infected patients and used for preparation of some of the first-generation HBV vaccines [20]. This similarity could explain the identical immunogenicity and specificity induced by natural infection or complete vaccination with a preS1-, preS2- and S-containing hepatitis B vaccine.
Five of 28 (18%) newborns lacked detectable levels of anti-preS1 (21–32), anti-preS1 (32–47) or anti-preS1 (94–117) antibodies. One explanation for this observation could be that the preS1 (21–32; 32–47 and 94–117) non-reactive patients have conformation dependent anti-preS1 antibodies in the circulation that are not reactive with the linear peptide analogues of preS1 (21–32, 32–47 and 94–117) used in this study. In most cases synthetic peptides are considered unsuitable for studying the discontinuously conformational epitopes because most peptide-specific antibodies are continuous sequence-specific [27]. The three-dimensional structure of the HBV surface protein, including preS1, has not yet been determined, though Lian et al [28] recently demonstrated that amino acids 31–36 were pivotal for the folding and conformational stability of the preS protein.
We demonstrated that those newborns that developed antibody reactivity against two or three B-cell epitopes had a significantly stronger anti-HBs response than those individuals that showed a narrower preS1 response. In congenic mice inclusion of preS regions elicits a broader spectrum of protective antibodies that augment the anti-HBs response and circumvent non-responsiveness to the S protein [26].
The preS1 region in humans has been shown to be a particularly efficient immunogen at the T-cell level. A dominant T-cell recognition site was identified in the N-terminal residues 21–28 (serotype adw) of the preS1 sequence [29,30] and in vitro binding studies have defined preS1 (25–33) as a promising helper T-cell epitope [31]. Further studies will show whether preS1 T-cell epitopes contained within the third-generation hepatitis B vaccine can mediate helper T-cell functions on the human antibody response to the particulate HBsAg similarly to what has been shown in the mouse system.
List of abbreviations
HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; Anti-HBc: antibody to hepatitis B core antigen; Anti-HBs: antibody to hepatitis B surface antigen; ALT: alanine aminotransferase; OD: optical density; N: normal; S: sample.
Financial competing interest
This study has been partly financed by SciGen Ltd, Singapore
Authors' contributions
UBH, KM and SPES participated in developing the study concept, research design, and analytical approach; interpreting the data; and developing the manuscript (writing or giving substantive input).
Acknowledgements
The authors cordially thank Dr Jolanta Mikolajewicz for organising the immunisation team.
TiollaisPPourcelCDejeanAThe hepatitis B virusNature (London)198531848995299583510.1038/317489a0BrussVThomssenRMapping a region of the large envelope protein required for hepatitis B virion maturationJ Virol1994681643508107225BlanchetMSureauCInfectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residuesJ Virol200781584191737692510.1128/JVI.00096-07NeurathARKentSBStrickNParkerKIdentification and chemical synthesis of a host cell receptor binding site on hepatitis B virusCell19864642936301541410.1016/0092-8674(86)90663-XNeurathARSetoBStrickNAntibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protectiveVaccine1989723436247689310.1016/0264-410X(89)90235-1PetitMADubanchetSChapelFVoetPDauguetCHauserPHepG2 cell binding activities of different hepatitis B virus isolates: inhibitory effect of anti-HBs ant anti-preS1(21–47)Virology199118048391170336810.1016/0042-6822(91)90062-GPontissoPPetitMABankowskiMJPeeplesMEHuman liver plasma membrane contains receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 regionJ Virol198963198182649690GriponPCannieIUrbanSEfficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface proteinJ Virol2005791613221565018710.1128/JVI.79.3.1613-1622.2005HeermannK-HKruseFSeiferMGerlichWHImmunogenicity of the gene S and pre-S domains in hepatitis B virions and HBsAg filamentsIntervirology1987281425244826410.1159/000149993MilichDRMclachlanAMoriartyAThorntonGBA single 10-residue pre-S1 can prime T cell help for antibody production to multiple epitopes within the pre-(S1), pre-S(2). and S regions of HBsAgJ Immunol19871384457652438344FerrariCCavalliAPennaABertolottiAPedrettiGPilliMVitaliPNeriTMGiubertiTFine specificity of the human T-cell response to hepatitis B virus preS1 antigenGastroenterology1992103255631377142KurokiKFloeraniMMimmsLTGanemDEpitope mapping of the preS1domain of hepatitis B virus large surface proteinVirology19901766204169324910.1016/0042-6822(90)90032-MParkJHChoEWLeeYJShinSYKimKLDetermination of the protective effects of neutralizing anti-hepatitis B virus (HBV) immunoglobulins by epitope mapping with recombinant HBV surface antigen proteinMicrobiol Immunol2000447031011021401MaengCYRyuCJGriponPGuguen-GuillouzoCHongHJFine mapping of virus-neutralizing epitopes on hepatitis B virus preS1Virology20002709161077297510.1006/viro.2000.0250HongHJRyuCJHurHKimSOhHKOhMSParkSYIn vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody chimpanzeesVirology2004318134411497254210.1016/j.virol.2003.09.014MilichDRSynthetic peptides: prospects for vaccine developmentSem Immunol1990530715PrideMWBaileyCRMuchmoreEThanavalaYEvaluation of B and T-cell responses in chimpanzees immunized with hepagene, a hepatitis B vaccine containing pre-S1, pre-S2 gene productsVaccine1998654350956946310.1016/S0264-410X(97)00242-9HuiJLiGKongYWangYExpression and characterization of chimeric hepatitis B surface antigen particles carrying preS epitopeJ Biotechnol19997249591040609810.1016/S0168-1656(99)00049-8ShouvalDHepatitis B vaccinesJ Hepatol200339S70761470868110.1016/S0168-8278(03)00152-1Rendi-WagnerPShouvalDGentonBLurieYRümkeHBolandGCernyAHeimMBachDSchroderMKollaritschHComparative immunogenicity of PreS/S hepatitis B vaccine in non- and low responders to conventional vaccineVaccine200624278191645516910.1016/j.vaccine.2006.01.007MadalinskiKSylvanSPHellstromUMikolajewiczJDzierzanowska-FangratKPresence of anti-PreS1, anti-preS2, and anti-HBs antibodies in newborns immunized with Bio-Hep-B vaccineMed Sci Monit200410P1107MadalinskiKSylvanSPHellströmUMikolajewiczJZembrzuska-SadowskaEPiontekEAntibody responses to preS components after immunization of children with low doses of BioHepBVaccine20012011334010.1016/S0264-410X(01)00312-7De MeyerSGongZJSuwandhiWvan PeltJSoumillionAYapSHOrgan and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytesJ Viral Hepatitis199741455310.1046/j.1365-2893.1997.00126.xAlbertiACavallettoDChemelloLBelussiFFattovichGPontissoPMilanesiGRuolAFine specificity of human antibody response to the preS1 domain of Hepatitis B virusHepatology19902199203239106310.1002/hep.1840120204HellstromULindhMKroogsgardKSylvanSDemonstration of an association between detection of IgG antibody reactivity towards the C-terminal region of the preS1 protein of hepatitis B virus and the capacity to respond to interferon therapy in chronic hepatitis BJ Gastroenterol Hepatol20082380410Epub 2007 Oct 101793137110.1111/j.1440-1746.2007.05174.xMilichDRMcLachlanAChisariFVKentSThorntonGImmune response to the preS (1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S (2) and S regions of HBsAgJ Immunol1986137315232423607MilichDRJonesJEMcLachlanABitterGMoriartyAHughesJLImportance of subtype in the immune response to the pre-S (2) region of the hepatitis B surface antigen II. Synthetic PreS (2) immunogenJ Immunol19901443544511691763LianMZhouXChenBLiCGuXLuoNZhengXIdentification of the critical regions in hepatitis B virus preS required for its stabilityJ Pept Sci2007JinYShihW-KBerkowerIHuman T cell response to the surface antigen of Hepatitis B virus (HBsAg)J Exp Med1988168293306245636910.1084/jem.168.1.293FerrariCPennaABertolettiACavalliAValliASchianchiCFiaccadoriFThe preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in manJ Clin Invest198984131419252926810.1172/JCI114299KimJHParkJHLeeYJChoEWBaeYSKimKLIn vitro binding analysis of hepatitis B virus preS-derived putative helper T-cell epitopes to MHC class II molecules using stable HLA-DRB1*0405/DRA*0101 transfected cellsIUBMB Life2000503798411327311